Rock Creek Group LP Acquires 340 Shares of Eli Lilly and Company (NYSE:LLY)

Rock Creek Group LP grew its holdings in Eli Lilly and Company (NYSE:LLY) by 35.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,291 shares of the company’s stock after purchasing an additional 340 shares during the quarter. Rock Creek Group LP’s holdings in Eli Lilly and were worth $296,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Knowledge Leaders Capital LLC grew its position in shares of Eli Lilly and by 1.2% during the second quarter. Knowledge Leaders Capital LLC now owns 3,320 shares of the company’s stock worth $762,000 after acquiring an additional 40 shares during the last quarter. Sage Rhino Capital LLC grew its position in Eli Lilly and by 2.1% in the 2nd quarter. Sage Rhino Capital LLC now owns 2,087 shares of the company’s stock valued at $479,000 after buying an additional 42 shares during the last quarter. Atlas Capital Advisors LLC grew its position in Eli Lilly and by 64.6% in the 2nd quarter. Atlas Capital Advisors LLC now owns 107 shares of the company’s stock valued at $25,000 after buying an additional 42 shares during the last quarter. Baker Tilly Wealth Management LLC grew its position in Eli Lilly and by 1.0% in the 2nd quarter. Baker Tilly Wealth Management LLC now owns 4,460 shares of the company’s stock valued at $1,024,000 after buying an additional 44 shares during the last quarter. Finally, Valmark Advisers Inc. grew its position in Eli Lilly and by 1.3% in the 2nd quarter. Valmark Advisers Inc. now owns 3,605 shares of the company’s stock valued at $827,000 after buying an additional 45 shares during the last quarter. Institutional investors and hedge funds own 81.65% of the company’s stock.

LLY has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Eli Lilly and from $270.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, August 4th. The Goldman Sachs Group raised their target price on Eli Lilly and from $252.00 to $270.00 and gave the company a “conviction-buy” rating in a report on Monday, June 14th. Argus raised their target price on Eli Lilly and from $225.00 to $300.00 and gave the company a “buy” rating in a report on Monday, August 9th. Mizuho raised their target price on Eli Lilly and from $250.00 to $279.00 and gave the company a “buy” rating in a report on Wednesday, August 4th. Finally, Morgan Stanley raised their target price on Eli Lilly and from $207.00 to $275.00 and gave the company an “overweight” rating in a report on Wednesday, August 4th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Eli Lilly and currently has a consensus rating of “Buy” and a consensus target price of $250.41.

Shares of LLY stock opened at $233.09 on Wednesday. The firm has a 50-day moving average price of $251.93 and a 200 day moving average price of $218.56. Eli Lilly and Company has a twelve month low of $129.21 and a twelve month high of $275.87. The company has a market capitalization of $223.54 billion, a price-to-earnings ratio of 34.95, a PEG ratio of 1.86 and a beta of 0.25. The company has a current ratio of 1.15, a quick ratio of 0.89 and a debt-to-equity ratio of 2.21.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Monday, August 2nd. The company reported $1.87 earnings per share for the quarter, missing the consensus estimate of $1.89 by ($0.02). The firm had revenue of $6.74 billion during the quarter, compared to analyst estimates of $6.59 billion. Eli Lilly and had a net margin of 22.71% and a return on equity of 119.12%. The company’s revenue for the quarter was up 22.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.89 EPS. As a group, research analysts predict that Eli Lilly and Company will post 7.87 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 10th. Shareholders of record on Friday, August 13th were issued a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 1.46%. The ex-dividend date of this dividend was Thursday, August 12th. Eli Lilly and’s dividend payout ratio (DPR) is 42.88%.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 202,102 shares of Eli Lilly and stock in a transaction dated Friday, July 2nd. The stock was sold at an average price of $232.94, for a total value of $47,077,639.88. Following the completion of the sale, the insider now owns 109,251,475 shares in the company, valued at approximately $25,449,038,586.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 1,044,132 shares of company stock valued at $257,735,592 in the last 90 days. 0.13% of the stock is owned by company insiders.

About Eli Lilly and

Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.

See Also: Bond

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.